Taiwan FDA registration 214a4b3952b7d23a21dcf2e55c78c8ca
CJ Rapitest CEA test kit
TW: 啟哲速測家癌胚抗原檢測試劑組
Taiwan·Risk Class 2·MD·Qizhe Biotechnology Co., Ltd·Registered Apr 21, 2017 – Apr 21, 2022ExpiredRegistration details
- Analysis ID
- 214a4b3952b7d23a21dcf2e55c78c8ca
- License Form
- Ministry of Health Medical Device Manufacturing No. 005603
Company information
- Manufacturer
- Qizhe Biotechnology Co., Ltd
- Manufacturer Country
- Taiwan, Province of China
- Authorized Representative
- Qizhe Biotechnology Co., Ltd
Product details
- Intended Use
- This product qualitatively detects carcinoembryonic antigen (CEA) in human serum.
- Product Type (Level 1)
- C Immunology and microbiology devices
- Product Type (Level 2)
- C6010 Tumor-associated antigen immunoassay system
- Import Information
- Produced in Taiwan, China
Dates and status
- Registration Date
- Apr 21, 2017
- Expiry Date
- Apr 21, 2022
About this record
Access comprehensive regulatory information for CJ Rapitest CEA test kit in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 214a4b3952b7d23a21dcf2e55c78c8ca and manufactured by Qizhe Biotechnology Co., Ltd. The authorized representative in Taiwan is Qizhe Biotechnology Co., Ltd.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices